In This Article:
MISSISSAUGA, Ontario, March 20, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2024 Annual Meeting of Shareholders ("AGM") held March 19, 2025.
Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors and the appointment of auditors. The total number of shares represented, either in person or by proxy, totaled 11,189,231 or 40.839%. The voting results are detailed below.
1. The Election of the Board of Directors
| Name of Nominee | Votes FOR | % | Votes WITHHELD | % |
| Brent Ashton | 10,857,752 | 99.995 | 500 | 0.005 |
| Amir Boloor | 10,842,550 | 99.855 | 15,702 | 0.145 |
| Joseph Cordiano | 10,837,850 | 99.812 | 20,402 | 0.188 |
| Martin Goldfarb | 10,671,750 | 98.282 | 186,502 | 1.718 |
| Samantha Nutt | 10,818,716 | 99.636 | 39,536 | 0.364 |
| Abe Schwartz | 10,837,850 | 99.812 | 20,402 | 0.188 |
| Ron Smith | 10,842,750 | 99.857 | 15,502 | 0.143 |
2. The Appointment of the Auditor
|
| Votes FOR | % | Votes WITHHELD | % |
| PricewaterhouseCoopers, LLP | 11,184,679 | 99.961 | 4,352 | 0.039 |
Final voting results of all matters voted on at the meeting will be filed on SEDAR+ at http://www.sedarplus.ca/ and further details of the voted matters can be found in the Company’s management information circular February 11, 2025.
A copy of management’s presentation is available on Covalon’s website at https://ir.covalon.com/events-and-presentations/events/event-details/2025/Annual-Meeting-of-Shareholders-2025-QA4l0L8ZN2/default.aspx. A recording of the AGM will also be made available on that page in the near future.
Those interested in learning more about Covalon’s solutions may visit www.covalon.com or follow Covalon on LinkedIn, Facebook, or Instagram, or X.
About Covalon
Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.